V2X Cops U.S. Space Contract
V2X Inc. (NYSE: VVX), out of Reston, Va. announced Wednesday has been awarded a new five-year task order to support U.S. Space Force operations at Ascension Island as part of the U.S. Air Force's Contract Augmentation Program V (AFCAP V). This morning’s news release reported the firm-fixed-price award includes a one-year base period and four one-year option periods, with a ceiling value of $140 million.Ascension Island is a key strategic location in the South Atlantic, supporting U.S. Space Force operations and the broader Eastern Range mission. Under this contract, V2X will deliver essential services that improve mission outcomes, operational efficiency, and infrastructure resilience on the island."Ascension Island plays a significant role in advancing the U.S. Space Force mission, and we're proud to support this national security asset," said CEO Jeremy C. Wensinger. "We will leverage our full lifecycle capabilities and decades of experience operating at scale in remote and dynamic environments to deliver improved readiness for this strategically vital mission."Also from this morning’s release, “V2X continues to be a trusted partner under the AFCAP V, the company's consistent performance under the program stresses its ability to deliver agile, reliable, and high-quality support services at scale across the globe. Operations are set to begin July 2025, reinforcing V2X's commitment to supporting full-spectrum solutions.” VVX shares began Wednesday at $49.05.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


